Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib

Product Details
Customization: Available
Powder: Yes
Customized: Negotiable
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2025

Suppliers with verified business licenses

Registered Capital
1000000 RMB
Plant Area
101~500 square meters
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
  • Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Find Similar Products
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
QS-Trametinib
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Children, Adult
State
Powder
Purity
>99%
Product Name
Trametinib
Name
Trametinib Powder
Appearance
White Powder
Colour
White
Grade
Pharmaceutical Grade
Assay
>99%
Application
API
Specific
COA
Test Method
HPLC
CAS
871700-17-3
Mf
C26h23fin5o4
MW
615.402623
Density
1.743
Melting Point
293-303c
Psa
110.62000
Transport Package
Negotiable
Specification
>99%
Trademark
QS-Trametinib
Origin
Xian
Production Capacity
1000kg/Month

Product Description

Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Product Description
Chemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Product Details
Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Product Name Trametinib
Appearance White Powder
Assay 99%
MW 615.402623
MF  C26H23FIN5O4
Trametinib is an oral bioavailable mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2 inhibitor, with potential anti-tumor activity.
Trametinib is a targeted therapy that targets the MEK 1 and MEK 2 protein (kinase) within the cancer cell. It is usually given in combination with a BRAF kinase inhibitor. The BRAF gene plays an important role in both normal and cancer cells. This gene leads to the production of BRAF protein.

Trametinib is an anti-cancer drug. It is a MEK inhibitor drug with anticancer activity. It inhibits MEK1 and MEK2. Trametinib has a good effect on metastatic melanoma with BRAF V600E mutation in a phase III clinical trial. In this mutation, the amino acid valine (V) at position 600 in the BRAF protein has been replaced by glutamic acid, making the mutant BRAF protein constitutively active.

Application&Function
Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib1. Analgesic effect
2. Reduce fever
3. Relieve muscle cramps
In summary, trametinib is a commonly used analgesic drug that is primarily used to relieve mild to moderate pain and can reduce pain through interaction with the central nervous system. In addition, it can also be used to treat fever, muscle cramps and other conditions, is an important drug in pain management. However, like all medicines, trametinib also needs to be used properly under the guidance of a doctor to avoid unnecessary risks.

Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Specification
Chemical Intermediate Raw Trametinib Anti-Cancer Trametinib
Chemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer TrametinibChemical Intermediate Raw Trametinib Anti-Cancer Trametinib

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier